Breast cancer

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 4, 2010, Pages 335-339

  Barrett, Sv ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Adjuvant therapy; Breast cancer; Mastectomy; Screening

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; EXEMESTANE; LAPATINIB; LETROZOLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; HUMAN; MAMMOGRAPHY; MASTECTOMY; METASTASIS POTENTIAL; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PROGNOSIS; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; FEMALE; GREAT BRITAIN; HUMANS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79551637788     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.418     Document Type: Article

References (10)

1. National Institute for Health and Clinical Excellence. Breast cancer (early & locally advanced): diagnosis and treatment. London: NICE; 2009. Available from: http://guidance.nice.org.uk/CG80
2. NHS Breast Screening Programme: http://www.cancerscreening.nhs.uk.
3. Duffy SW, Tabar L, Olsen AH et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 2010; 17:25-30. doi:10.1258/jms.2009.009094
4. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14:8019-26. doi:10.1158/1078-0432.CCR-08-0974
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087-106. doi:10.1016/S0140-6736(05)67887-7
6. START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371:1098-107. doi:10.1016/S0140-6736(08)60348-7
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717. doi:10.1016/S0140-6736(05)66544-0
8. MINDACT. Phase III randomized study of 70-gene signature versus clinical assessment in selecting women with 0-3 positive nodes breast cancer for adjuvant chemotherapy. National Cancer Institute, 2006-19. Available from: http://www.cancer.gov/clinicaltrials/EORTC-10041
9. TAILORx. Phase iii randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary nodenegative breast cancer with various levels of risk for recurrence. National Cancer Institute, 2006-14. Available from: http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72. doi:10.1056/NEJMoa052306